Zydus Lifesciences Limited, a global healthcare company, has announced its agreement to acquire a majority stake in Amplitude Surgical, a European surgical device maker specializing in lower-limb orthopedic technologies. Under the deal, Zydus Lifesciences will acquire 85.6% of Amplitude Surgical for €256.8M ($277.4M).
Amplitude Surgical has experienced significant growth over the past four years driven by new product development, international expansion, investments in manufacturing capabilities, and research and development. The company’s products, including the AMPLIVISION, i.M.A.G.E., and E.T.O.I.L.E. platforms, aim to improve fitting accuracy and enable less-invasive surgical approaches.
Zydus Lifesciences Managing Director, Dr. Sharvil Patel, expressed the company’s commitment to quality excellence, continuous investments in R&D, and expertise in manufacturing, which will guide its entry into the highly specialized MedTech products. He believes the deal presents medium-term and long-term growth opportunities in terms of portfolio, capabilities, manufacturing, and geographies.
The agreement is subject to completing definitive agreements and obtaining approval from the Autorité des Marchés Financiers (AMF), the securities commission in France, by June 2025. The potential acquisition is expected to expand Zydus Lifesciences’ portfolio and capabilities in the MedTech industry, creating new opportunities for growth and innovation.
The press releases from Zydus Lifesciences, Amplitude Surgical, and PAI Partners, the private equity firm involved in the deal, are available online, providing further details on the agreement and its implications.